AURORA DOGARU: Open Payments
NPI 1013948744 · SCARSDALE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,001 in 70 payments from 10 companies in 2025. Trend: 2023 $3,478 · 2024 $3,524 · 2025 $5,001
Food & beverage: $5,001
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $1,157 |
| E.R. Squibb & Sons, L.L.C. | 12 | $858 |
| Otsuka America Pharmaceutical, Inc. | 10 | $653 |
| Lilly USA, LLC | 5 | $621 |
| Axsome Therapeutics, Inc. | 6 | $484 |
| Janssen Pharmaceuticals, Inc | 3 | $416 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $402 |
| Teva Pharmaceuticals USA, Inc. | 3 | $159 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $127 |
| Grifols USA, LLC | 1 | $125 |
Products named: VRAYLAR, COBENFY, KISUNLA, Auvelity, INVEGA SUSTENNA, REXULTI, CAPLYTA, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
